Vanguard Group Inc Castle Biosciences Inc Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Castle Biosciences Inc stock. As of the latest transaction made, Vanguard Group Inc holds 2,170,028 shares of CSTL stock, worth $49.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,170,028
Previous 2,047,565
5.98%
Holding current value
$49.4 Million
Previous $41 Million
8.1%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CSTL
# of Institutions
165Shares Held
27.2MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY3.04MShares$69.3 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.8MShares$40.9 Million0.02% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.49MShares$33.9 Million2.2% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.38MShares$31.3 Million0.01% of portfolio
-
Nuveen, LLC Charlotte, NC1.07MShares$24.4 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $598M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...